MedPath

Eicosapentaenoic acid in the treatment of pediatric atopic dermatitis

Phase 3
Conditions
Atopic dermatitis.
Other atopic dermatitis
Registration Number
IRCT20170608034390N2
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Pediatric patients with atopic dermatitis aged 6 months to 13 years

Exclusion Criteria

Age greater than 13 years
Extent of skin involvement less than 2% or more than 30% of the body surface
Other skin problems other than atopic dermatitis

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Severity of eczema. Timepoint: Measuring the severity of eczema at the beginning of the study (before the intervention) and 2 and 4 days after starting the drug. Method of measurement: Based on a SCORing Atopic Dermatitis (SCORAD) Calculator.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath